Full name
NARODOWY INSTYTUT ONKOLOGII IM. MARII SKŁODOWSKIEJ-CURIE - PAŃSTWOWY INSTYTUT BADAWCZY
uses securityreCAPTCHA
72.19.Z - Scientific research and development activities
21.20.Z - Manufacture of pharmaceutical preparations and other pharmaceutical products
55.10.Z - Hotels and similar accommodation establishments
68.20.Z - Rental and management of own or leased real estate
72.11.Z - Scientific research and development activities
73.10.F - Advertising, market research and public relations
86.10.Z - Hospital activities
86.22.Z - Specialist medical practice
86.90.A - Healthcare
86.90.E - Healthcare
2021 | 2022 | 2023 | ||
---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Gross profit (loss) | -4,4 | 34,6 | 94,7 | 173,8 |
EBITDA | 129,6 | 174,3 | 212,1 | 21,7 |
Short time liabilities | 352,6 | 306,2 | 345,8 | 12,9 |
Equity capital | 215,1 | 244 | 337,2 | 38,2 |
Operating profit (EBIT) | 4,8 | 48,7 | 97,9 | 101,1 |
Assets | 1175,2 | 1305,4 | 1565,4 | 19,9 |
Net profit (loss) | -5,8 | 32,6 | 93,2 | 185,9 |
Cash | 183,2 | 255 | 310,3 | 21,7 |
Liabilities and provisions for liabilities | 960,1 | 1061,5 | 1228,2 | 15,7 |
Net income from sale | 1767,5 | 2023,6 | 2391,6 | 18,2 |
Working assets | 479,1 | 562,4 | 708 | 25,9 |
Depreciation | 124,8 | 125,6 | 114,2 | -9,1 |
% | % | % | p.p. | |
Profitability of capital | -2,7 | 13,4 | 27,6 | 14,2 |
Equity capital to total assets | 18,3 | 18,7 | 21,5 | 2,8 |
Gross profit margin | -0,2 | 1,7 | 4 | 2,3 |
EBITDA Margin | 7,3 | 8,6 | 8,9 | 0,3 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 73 | 55 | 53 | -2 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane